Whanin Pharm (016580) — Cash Flow-to-Debt Ratio
Whanin Pharm (016580) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of ₩2.38 Billion could theoretically repay 0% of its total liabilities (₩57.88 Billion) in one year. See Whanin Pharm free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Whanin Pharm Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for Whanin Pharm across 13 annual periods. Also explore 016580 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Whanin Pharm (2009–2025)
Year-by-year debt coverage analysis for Whanin Pharm. For market capitalisation and broader financial context, see market cap of Whanin Pharm.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | ₩9.04 Billion | ₩57.88 Billion | ▼ -63.2% |
| 2024 | 0.42x | ₩20.69 Billion | ₩48.70 Billion | ▼ -21.2% |
| 2023 | 0.54x | ₩23.20 Billion | ₩43.02 Billion | ▲ +13.4% |
| 2022 | 0.48x | ₩16.85 Billion | ₩35.45 Billion | ▼ -51.6% |
| 2021 | 0.98x | ₩35.32 Billion | ₩35.96 Billion | ▲ +42.2% |
| 2020 | 0.69x | ₩22.75 Billion | ₩32.96 Billion | ▼ -15.1% |
| 2019 | 0.81x | ₩24.73 Billion | ₩30.42 Billion | ▲ +30.9% |
| 2018 | 0.62x | ₩17.45 Billion | ₩28.10 Billion | ▼ -16.0% |
| 2017 | 0.74x | ₩23.48 Billion | ₩31.75 Billion | ▼ -13.0% |
| 2016 | 0.85x | ₩19.82 Billion | ₩23.31 Billion | ▼ -23.9% |
| 2012 | 1.12x | ₩21.11 Billion | ₩18.90 Billion | ▲ +20.1% |
| 2011 | 0.93x | ₩15.12 Billion | ₩16.25 Billion | ▼ -47.5% |
| 2009 | 1.77x | ₩18.61 Billion | ₩10.51 Billion | — |